Recombinant protein COVID 19 vaccine - West China Hospital Sichuan University/WestVac Biopharma
Alternative Names: Coviccine; Recombinant COVID-19 vaccine (Sf9 cells); Recombinant SARS-CoV-2 vaccine (Sf9 Cells)Latest Information Update: 11 Apr 2025
At a glance
- Originator West China Hospital Sichuan University
- Developer West China Hospital Sichuan University; Westvac Biopharma
- Class COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 24 Mar 2025 WestVac Biopharma withdrew prior to enrolment a phase I/II trial in COVID-2019 infections (Prevention, In children, In adolescents) in China (IM, Injection), as the study was not initiated (NCT05013983)
- 30 Dec 2023 WestVac Biopharma completes a clinical trial for COVID-2019 infections (In volunteers) in China (IM) (NCT05465785)
- 01 Nov 2023 WestVac Biopharma completes a phase III trial in COVID-2019 infections (Prevention, In adults, In the elderly) in China (IM) (NCT04904471)